Zilovertamab vedotin
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer[1].
Product Specifications
Product Name Alternative
VLS-101; MK-2140
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zilovertamab-vedotin.html
Purity
98.61
Solubility
10 mM in DMSO
Smiles
[Zilovertamabvedotin]
Molecular Weight
151000 (average)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Human Disrupted In Renal Carcinoma Protein 1 (DIRC1) ELISA Kit
Human Disrupted In Renal Carcinoma Protein 1 (DIRC1) ELISA Kit
Human Disrupted In Renal Carcinoma Protein 1 (DIRC1) ELISA Kit
Human Disrupted In Renal Carcinoma Protein 1 (DIRC1) ELISA Kit